AEON Biopharma, Inc. (AEON)
- Previous Close
0.4931 - Open
0.4931 - Bid 0.4999 x 1000
- Ask 0.5550 x 3000
- Day's Range
0.4900 - 0.5600 - 52 Week Range
0.3750 - 269.2800 - Volume
829,212 - Avg. Volume
3,150,230 - Market Cap (intraday)
5.323M - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
0.00 - EPS (TTM)
303.0800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
www.aeonbiopharma.comRecent News: AEON
View MorePerformance Overview: AEON
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AEON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AEON
View MoreValuation Measures
Market Cap
5.32M
Enterprise Value
9.48M
Trailing P/E
0.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-158.88%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
169.12M
Diluted EPS (ttm)
303.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
10.45M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.17M